{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:27Z","timestamp":1780920687573,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Vetmedica Japan Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101127","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:02:44Z","timestamp":1770134564000},"page":"101127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer"],"prefix":"10.1016","volume":"47","author":[{"given":"Koichi","family":"Azuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101127_bib0001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev-med-051718-013524","article-title":"Precision management of advanced non-small cell lung cancer","volume":"71","author":"Yang","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ctarc.2026.101127_bib0002","first-page":"2892","article-title":"EGFR mutation incidence in non-small cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer. ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0004","series-title":"National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer","year":"2023"},{"key":"10.1016\/j.ctarc.2026.101127_bib0005","first-page":"1","article-title":"Immunotherapy for advanced non-small lung cancer: a decade of progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ctarc.2026.101127_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ctarc.2026.101127_bib0007","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2026.101127_bib0008","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0009","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0010","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0011","first-page":"1","volume":"00","author":"Yang","year":"2024","journal-title":"Phase III KEYNOTE 789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer"},{"key":"10.1016\/j.ctarc.2026.101127_bib0012","first-page":"62","article-title":"Breaking boundaries: chronic diseases and the frontiers of immune microenvironments","volume":"1","author":"Li","year":"2025","journal-title":"Med Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0013","article-title":"The role of tumor microenvironment in the progression and treatment of chronic liver diseases","volume":"37","author":"Wang","year":"2024","journal-title":"Drug Discov. Today Dis. Models"},{"key":"10.1016\/j.ctarc.2026.101127_bib0014","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","article-title":"A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L)","volume":"28","author":"Hayashi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of freely available easy-to-use software `EZR` for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"W1","key":"10.1016\/j.ctarc.2026.101127_bib0016","doi-asserted-by":"crossref","first-page":"W317","DOI":"10.1093\/nar\/gkab447","volume":"49","author":"Dechao","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101127_bib0017","volume":"39","author":"Marcos","year":"2023","journal-title":"Bioinformatics"},{"issue":"D1","key":"10.1016\/j.ctarc.2026.101127_bib0018","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0019","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00262-024-03781-8","article-title":"Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1\/L1 inhibitor monotherapy","volume":"73","author":"Murata","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ctarc.2026.101127_bib0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"issue":"7793","key":"10.1016\/j.ctarc.2026.101127_bib0021","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101127_bib0022","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0023","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations ALK rearrangements are associated with low response to PD-1 pathway in non-small cell cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0024","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103494","article-title":"Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure","volume":"9","author":"Huang","year":"2024","journal-title":"ESMo Open"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101127_bib0026","first-page":"555","article-title":"Chemotherapy and mutational processes in cancer evolution","volume":"17","author":"McGranahan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101127_bib0027","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and its impact on clinical outcomes","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"6230","key":"10.1016\/j.ctarc.2026.101127_bib0028","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101127_bib0029","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101127_bib0030","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clinic. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0031","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune -related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0032","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0033","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.cllc.2020.02.012","article-title":"Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer","volume":"21","author":"Miyawaki","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101127_bib0034","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101127_bib0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2023.02.010","article-title":"RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC(EGFR+NSCLC): association between TP53 status and clinical outcome","volume":"24","author":"Nishio","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101127_bib0036","first-page":"17","volume":"106","author":"Vanderlaan","year":"2017","journal-title":"Mutations I TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes"},{"key":"10.1016\/j.ctarc.2026.101127_bib0037","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat. Rev. Clinic. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101127_bib0038","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0039","article-title":"TP53 mutations as potential biomarkers for predicting response to immune checkpoint inhibitors in lung adenocarcinoma: insights from integrative analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101127_bib0040","article-title":"Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"478","author":"Sun","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ctarc.2026.101127_bib0041","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101127_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814212","article-title":"SYNE1 mutation is associated with increased tumor mutation burden and immune cell infiltration in ovarian cancer","volume":"24","author":"Harbin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101127_bib0043","doi-asserted-by":"crossref","first-page":"19316","DOI":"10.18632\/aging.103781","article-title":"SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients","volume":"12","author":"Li","year":"2020","journal-title":"Aging"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:47:10Z","timestamp":1780919230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":43,"alternative-id":["S2468294226000389"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101127","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101127"}}